3D silk-fibroin
Drug Research
Large-scale production
Ex vivo platelets

Why use SilkFusion system

SilkFusion is a groundbreaking 3D silk-fibroin technology for ex-vivo large-scale production of blood platelets for human transfusion from human pluripotent stem cells (hPSCs). Its core technology combines genetically engineered human pluripotent stem cells differentiating into megakaryocytes and functionalized silk-fibroin platforms and bio-inks to release the platelets from the megakaryocytes.

3D technology

3D silk-fibroin technology for ex-vivo production of platelets for transfusions.

Personalized treatment

Immunologically-matched platelets to allow immunized patients. Enhanced coagulation.


Production of platelets for clinical transfusions in humans at an affordable cost.

Fast, scalable and self-sufficient

Large-scale platelet production in real time and upon demand.


High-fidelity reproducible printing of silk-based clinical instruments to improve disease diagnosis.

Biocompatible and safe

Pathogen-free material. Approved by EMA/FDA. Not thrombogenic.

The problem to solve

The limited supply of human platelets and the rapidly growing demand for medical research and clinical applications including studies of platelet-related disease mechanisms and platelet transfusions for patients, are manifest.

Due to the ageing population and ever more aggressive chemotherapies, platelet demand is increasing by 10% every year, while the supply of platelets is entirely dependent on allogenic donations. In Europe, the demand of platelets averages 5 units per 1,000 population per annum, i.e. 2.5 million units per year, costing over €375 million. Lastly, there is a clear need for reproducible solutions to assist patients with acute haemorrhage resulting from trauma, surgery and emergency treatment in conflict zones.